Direct Reprogramming of Human Fetal- and Stem Cell-Derived Glial Progenitor Cells into Midbrain Dopaminergic Neurons by Nolbrant, Sara et al.
Please cite this article in press as: Nolbrant et al., Direct Reprogramming of Human Fetal- and Stem Cell-Derived Glial Progenitor Cells into
Midbrain Dopaminergic Neurons, Stem Cell Reports (2020), https://doi.org/10.1016/j.stemcr.2020.08.013Stem Cell Reports
ArticleDirect Reprogramming of Human Fetal- and Stem Cell-Derived Glial
Progenitor Cells into Midbrain Dopaminergic Neurons
Sara Nolbrant,1 Jessica Giacomoni,1 Deirdre B. Hoban,1 Andreas Bruzelius,2 Marcella Birtele,1
Devin Chandler-Militello,3 Maria Pereira,1 Daniella Rylander Ottosson,2 Steven A. Goldman,3,4,5
and Malin Parmar1,*
1Developmental and Regenerative Neurobiology, Wallenberg Neuroscience Center, and Lund Stem Cell Centre, Department of Experimental Medical
Science, Lund University, Lund, Sweden
2Regenerative Neurophysiology, Wallenberg Neuroscience Center, Lund Stem Cell Center, Department of Experimental Medical Science, Lund University,
Lund, Sweden
3Center for Translational Neuromedicine and Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
4Center for Neuroscience, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark
5Neuroscience Center, Rigshospitalet, Copenhagen, Denmark
*Correspondence: malin.parmar@med.lu.se
https://doi.org/10.1016/j.stemcr.2020.08.013SUMMARYHuman glial progenitor cells (hGPCs) are promising cellular substrates to explore for the in situ production of new neurons for brain
repair. Proof of concept for direct neuronal reprogramming of glial progenitors has been obtained inmousemodels in vivo, but conversion
using human cells has not yet been demonstrated. Such studies have been difficult to perform since hGPCs are born late during human
fetal development, with limited accessibility for in vitro culture. In this study, we show proof of concept of hGPC conversion using fetal
cells and also establish a renewable and reproducible stem cell-based hGPC system for direct neural conversion in vitro. Using this system,
we have identified optimal combinations of fate determinants for the efficient dopaminergic (DA) conversion of hGPCs, thereby yielding
a therapeutically relevant cell type that selectively degenerates in Parkinson’s disease. The induced DA neurons show a progressive, sub-
type-specific phenotypic maturation and acquire functional electrophysiological properties indicative of DA phenotype.INTRODUCTION
Somatic cells can be directly converted into induced neu-
rons (iNs) without a stem cell intermediate using defined
sets of transcription factors, microRNAs, and/or through
chemical manipulations. Since the original report (Vierbu-
chen et al., 2010), a number of studies have shown conver-
sion of human fibroblasts into subtype-specific neurons,
including dopaminergic (DA) neurons, striatal medium
spiny neurons, peripheral sensory neurons, noradrenergic
neurons, cholinergic neurons, and spinal motor neurons
using different combinations of lineage specific transcrip-
tion factors (Blanchard et al., 2015; Caiazzo et al., 2011;
Li et al., 2019; Liu et al., 2013; Pfisterer et al., 2011; Son
et al., 2011; Victor et al., 2014). Direct neural conversion
opens up new possibilities to generate patient- and dis-
ease-specific neurons from somatic cells and is predicted
to have a great impact on disease modeling, diagnostics,
and other biomedical applications (Drouin-Ouellet et al.,
2017b; Mertens et al., 2018).
Direct conversion could potentially also be used to
generate neurons for transplantation-based cell replace-
ment therapies. So far, a number of somatic cell types,
including fibroblasts, hepatocytes, pericytes, and glia,
have been successfully converted to neurons (Masserdotti
et al., 2016). Since the direct conversion strategy does not
rely on a proliferative intermediate, some of the safety con-Stem
This is an open access article under the Ccerns associated with the use of human pluripotent stem
cells (hPSCs) are minimized, and both autologous and allo-
geneic strategies could be used (Fang et al., 2018; Grealish
et al., 2016). As an extension of direct conversion in cell-
based therapies, delivery of the conversion factors directly
to the brain with the aim of converting endogenous glia is
being developed as an alternative approach for the genera-
tion of therapeutic neurons in situ (Vignoles et al., 2019). In
support of this concept, resident astrocytes and glial pro-
genitor cells (GPCs, also called oligodendrocyte progenitor
cells or NG2 cells) have been successfully converted into
neurons in the mouse brain (Guo et al., 2014; Mattugini
et al., 2019; Niu et al., 2015; Pereira et al., 2017; Qian
et al., 2020; Rivetti di Val Cervo et al., 2017; Torper et al.,
2015). For translational applications, it is important to
document the conversion of human glia into subtype-spe-
cific and functional neurons. Initially, this can be done us-
ing in vitro cultures of human brain-derived cells and so far,
human astrocytes and pericytes have been shown to
generate functional and subtype-specific neurons after
conversion in vitro (Guo et al., 2014; Karow et al., 2012).
The possibility to convert human GPCs (hGPCs) in vitro
has not yet been explored even though these cells may be
more suitable than astrocytes for in situ conversion,
because GPCs remain proliferative in the adult brain
(Hughes et al., 2013; Simon et al., 2011). Proof of concept
for GPC conversion has been obtained in mouse modelsCell Reports j Vol. 15 j 1–14 j October 13, 2020 j ª 2020 The Authors. 1
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2017; Torper et al., 2015). However, studies of human GPC
conversion are challenging because GPCs are not born un-
til late in the second trimester, which limits their accessi-
bility because it is difficult to source human embryos for
cell isolation and subsequent in vitro cultures (Jakovcevski
and Zecevic, 2005; Sim et al., 2011).
In this study, we show that hGPCs isolated from the hu-
man fetal brain can be efficiently converted into neurons
in vitro, which provides important proof of concept for
the approach. However, access to human fetal cells is
limited, and we therefore sought to establish a human
pluripotent stem cell (hPSC)-based experimental model
system for hGPC reprogramming studies. To achieve this,
we differentiated human embryonic stem cells (hESCs)
into hGPCs, based on the protocol by Wang et al. (2013),
and show that these hESC-derived hGPCs convert into
iNs in a similar manner to the hGPCs isolated from the hu-
man fetal brain. We used stem cell-derived hGPCs to assess
the effect of fate-determining genes with a focus on DA
neurons, the principal neuronal subtype lost in Parkinson’s
disease (PD), and thus a therapeutically important cell type.
We found that hGPCs can be directly converted into TH+
neurons using several different combinations of transcrip-
tion factors and microRNAs. The resulting TH+ neurons
have a gene and protein expression profile similar to
mature midbrain DA neurons and adopt electrophysiolog-
ical properties typical of functional DA neurons.
Thus, this study provides evidence that hGPCs isolated
from both human fetal brain and differentiated from
hESCs can be successfully reprogrammed into functional
iNs, including induced DA neurons (iDANs).RESULTS
Human Fetal Glial Progenitors Efficiently Convert to
Functional iDANs In Vitro
To establish the potential of hGPCs to convert into neurons
in vitro, we used hGPCs isolated from the fetal brain
(Figures 1A, 1B and S1A–S1AC) (Benraiss et al., 2016) and
transduced them with doxycycline (dox)-inducible vectors
carrying the conversion factors Ascl1, Lmx1a, and Nr4a2
(Nurr1), (together refered to as ALN), a combination of fac-
tors that has previously been used to successfully repro-
gram human fetal fibroblasts into iDANs (Caiazzo et al.,
2011; Torper et al., 2013) together with short hairpin (sh)
RNA against the RE1-silencing transcription factor (REST)
complex. Already at 1 week after transgene activation, glial
markers were downregulated, and some TH+/MAP2+ cells
could be detected in the cultures (Figure S1D). After an
additional 2 weeks, the reprogrammed cells showed a
more pronounced neuronal morphology and expressed2 Stem Cell Reports j Vol. 15 j 1–14 j October 13, 2020many DA-related genes, including TH, SLC6A3 (DAT),
FOXA2, LMX1A, and PITX3 (Figures 1C, 1F, and S1E). Con-
trol cultures of untransduced cells that were kept in parallel
in either glial medium or neuronal conversion medium
(containing small molecules and growth factors)
continued to express GFAP and PDGFRa (Figures S1F and
S1G) and did not give rise to any TH+ neurons (Figures
1D and 1E).
Whole-cell patch-clamp recordings were performed after
80–120 days in vitro and confirmed functional maturation
of the hGPC-derived iNs. At this point, the reprogrammed
neurons (n = 37) exhibited the ability to fire evoked action
potentials (APs) in the form of single and multiple APs
(multiple APs, 14%; single APs, 22%; n = 37) (Figure 1G
and Table S1). The cells also displayed fast-inactivated in-
ward and outward currents characteristic of sodium and de-
layed-rectifier potassium currents (Figure 1H), as well as
spontaneous postsynaptic activity (Figure 1I), suggestive
of synaptic engagement. Moreover, a proportion of the
converted neurons developed spontaneous firing at resting
membrane potential (7/25 converted neurons; Figure 1J), a
characteristic typical of DA neurons.
Taken together, this establishes the ability of fetal hGPCs
to be reprogrammed into functional iNs, with a gene and
protein expression profile and functionality indicative of
a DA identity using ALN + shREST. However, hGPCs arise
late in the gestational time period, following the neuron-
to-glial cell switch, and are therefore difficult to obtain
from the limited amounts of fetal brain tissue available at
this late gestational time point (Rowitch and Kriegstein,
2010; Sim et al., 2011). To enable larger experimental
studies of hGPC conversion, we set out to develop a more
accessible experimental in vitro system.
Establishing a Pluripotent Stem Cell-Based Model
System for hGPC Reprogramming
To establish an in vitro model system for direct neuronal
conversion using cells that are as close as possible to the
bona fide hGPCs in the brain, we used a previously pub-
lished protocol for generating hGPCs from hPSCs (Wang
et al., 2013). The protocol was adapted to a defined and
xeno-free hESC culture system for maintenance of hPSCs
on recombinant human laminin, in iPS Brew medium.
We also established a cryopreservation step in order to
improve the logistics and reproducibility of the protocol
(Figure 2A). During the glial differentiation of the hESCs,
the proportion of cells positive for CD140 (PDGFRa),
which identifies myelinogenic and migration-competent
human oligodendrocyte progenitor cells (Sim et al.,
2011), increases with time in culture (Figure S2A). Cells
generated from two different hESC lines (RC17 and
HS1001) were expanded and cryopreserved from day 160
up to day 250 (Figures 2A and 2B). At this point. the
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Figure 1. Fetal hGPCs Can Be Converted to Induced DA Neurons In Vitro
(A and B) Fetal hGPCs visualized by bright field imaging (A) or stained for GFAP and PDGFRa (B).
(C) Reprogrammed TH+/TAU+ neurons 3 weeks after transgene activation.
(D and E) hGPCs kept in parallel for 3 weeks in neuronal conversion medium (D) or glial medium (E) do not give rise to any TH+/TAU+
neurons.
(F) qPCR analysis of reprogrammed cells 3 weeks after transgene activation shows an upregulation of pan-neuronal and DA genes.
(G) Representative trace of voltage responses from the whole-cell patch-clamp technique showing multiple induced APs.
(H) Representative trace of inward sodium- and outward potassium-rectifying currents triggered by stepwise depolarization of the cell.
(I and J) The reprogrammed fetal hGPCs show spontaneous postsynaptic currents (I) and spontaneous firing at their resting membrane
potential (J).
In Figure 1F, data are presented as means ± SEM, and all data points have been visualized in the graphs. Each data point represents a
replicate from an independent experiment (n = 5 for ALN + shREST; n = 2 for CNTRL-NDIFF; n = 3 for CNTRL-GM). Scale bars: (A, B, D, and E)
100 mm; (C) 50 mm. See also Figure S1.
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confirmed that this phenotype was maintained following
cryopreservation (Figures 2C, 2D, and S2A–S2E). The glial
marker CD44 labels astrocyte biased progenitors, or when
co-expressed with CD140, bipotential glial progenitors. In
contrast to CD140, the proportion of CD44+ cells did not
increase with time in culture (Figure S2A), and the cryo-
preservation procedure did not significantly affect the rela-tive proportion of CD44+ cells in the culture (p = 0.952;
paired, two-tailed t test). Under these culture conditions,
very few if any cells expressed neuronal TAU (HT7) or
MAP2a/MAP2b (Figures S2F and S2G), whereas MAP2c,
an isoformofMAP2 that is expressed in developing progen-
itors, both neuronal and oligodendroglial (Garner et al.,
1988; Vouyiouklis and Brophy, 1995), was abundantly ex-
pressed (Figure S2F). Rare TH+ cells could also be found inStem Cell Reports j Vol. 15 j 1–14 j October 13, 2020 3
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Figure 2. Establishing a Renewable and Reproducible Source of hGPCs from hESCs for In Vitro Modeling of Direct Neuronal Con-
version
(A) Schematic overview of the protocol for generating hESC-derived hGPCs, with an indication of the time frame used for cryopreservation.
(B) Bright-field images of the hESC-derived hGPCs cultures at different stages and before and after cryopreservation.
(C) GFAP/PDGFRa immunostaining of the hESC-derived hGPC cultures at different stages and before and 15 days after cryopreservation.
Insets show close-up morphology of cells in the boxed areas.
(D) Percentage of CD140+ cells within the cultures before and after cryopreservation as determined by flow cytometry.
(E and F) TH+/TAU+ cells (E) and NEUN+ cells (F) 3 weeks after activation of the transgenes ALN + shREST in hESC-derived hGPCs.
The proportions of CD140+ cells in Figure 2D were compared using a paired two-tailed t test; *p < 0.05 (p = 0.0327). Scale bars: 100 mm. See
also Figures S2 and S3.
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co-labeling with glial and neuronal markers confirmed
that these cells were of a glial identity, since TH was only
found co-labeled with glial markers and not with neuronal
markers (Figures S1C, S2G, and S2H).
We next assessed whether cryopreserved hESC-derived
hGPCs could be converted into iDANs using the same pro-
tocol and the same combination of reprogramming factors
(ALN + shREST) as was used for the fetal hGPCs. In accord
with our observations in converting fetal progenitors, some
TH+ neurons could be detected 1 week after conversion
(Figure S3A). Three weeks after activation of ALN + shREST,
the glial markers were efficiently downregulated, and the4 Stem Cell Reports j Vol. 15 j 1–14 j October 13, 2020cultures contained few if any GFAP+ or PDGFRa+ cells (Fig-
ure S3B). Control cells that were not transduced but
cultured in neuronal conversion medium (Figures S3C
and S3D), as well as control glial cultures that were
analyzed in parallel (Figure S3E), maintained their glial
identity (Figures S3D and S3E), and no TH+ neurons were
detected (Figure S3C). At this time point, reprogrammed
cells with a clear neuronal morphology that were positive
for TH/TAU and NEUN were observed only after reprog-
ramming with ALN + shREST (Figures 2E, 2F, and 5G).
Together, these data establish that both fetal hGPCs and
hESC-derived hGPCs can be converted to TH+ iNs, using
the same factors and with comparable timing and
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Figure 3. Direct Conversion of Purified CD140-expressing Progenitors
(A) Schematic overview of the strategy for neuronal conversion of CD140-sorted and unsorted cells side by side. Astrocyte biased pro-
genitors are depicted in green, oligodendrocyte biased progenitors are depicted in pink, bipotent glial progenitors are depicted in purple,
and cells of an unknown identity are depicted in blue.
(B and C) CD140-sorted hGPCs are positive for OLIG2/SOX10 (B) and PDGFRa (C). A subset of the hGPCs are positive for GFAP (B and C),
representing a bipotent progenitor state.
(D and E) TH+/TAU+ cells 3 weeks after reprogramming, starting from either unsorted (neuronal proportion, 53.7%; TH+ neuronal pro-
portion, 1.7%; D) or CD140-sorted (neuronal proportion, 57.0%; TH+ neuronal proportion, 1.3%; E) hESC-derived hGPCs.
Scale bars: (C) 100 mm; (B, D, and E) 50 mm. See also Figure S4.
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were noted between fetal- and hESC-derived cells in the
relative proportions of either neurons (p = 0.102) or TH+
neurons (p = 0.139; both determined using unpaired,
two-tailed t tests). These data support the applicability of
our stem cell-based model system for neuronal conversion
studies.
Purified Populations of hESC-Derived hGPCs Can Be
Converted to TH+ INs
We initiated conversion from hESC-derived hGPCs at
different time points, ranging from day 160 to day 270 in
culture (corresponding to passage 2–6 of the hGPCs; see Ta-
ble S2) and established that the time in culture did not
affect the efficiency of the hGPCs to convert into iNs, based
on the comparable induction of TH and SYNAPSIN 1
(SYN1) as assessed 3 weeks after initiation of reprogram-
ming (Figure S3F). The differentiation protocol used here
results in primarily oligodendrocyte biased progenitors
(CD140+/CD44) but also produces a minority of bipoten-
tial (CD140+/CD44+) and astrocyte biased (CD140/
CD44+) progenitors. By analyzing neuronal conversions
from different glial differentiation runs containing varyingratios of these three subtypes of glial progenitors (Table S2),
we found that the induction of SYN1 in the reprogrammed
cells correlated positively with a high CD140+ starting pop-
ulation, and negatively with a high astrocyte progenitor
population, while TH expression did not vary in correla-
tion with the composition of cells at the start of neuronal
conversion (Figure S3G).
To assess experimentally if a purified population of
CD140+ hGPCs can be converted into TH+ iNs, we next
used fluorescence-activated cell sorting to extract the
CD140+ fraction from the hESC-derived hGPCs cultures
(Figures 3A–3C and S4). Importantly, by converting un-
sorted cells (Figure 3D) and CD140-sorted cells (Figure 3E)
from the same batch of hESC-derived hGPCs side by side,
we confirmed that using our differentiation strategy,
CD140+ hGPCs are indeed amenable to DA conversion
in vitro.
Timed Delivery of Foxa2 Augments DA
Reprogramming of Fetal- and Stem Cell-Derived
hGPCs
Previous efforts from our lab and others have identified
Otx2, Foxa2, Nurr1, NeuroD1, Ascl1, Lmx1a, and mir218Stem Cell Reports j Vol. 15 j 1–14 j October 13, 2020 5
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Figure 4. Direct Conversion of hESC-Derived hGPCs Using Different Combinations of DA Fate Determinants
(A) Schematic overview of the neuronal conversion protocol indicating the different time points of analysis and references to the figures
related to each time point.
(legend continued on next page)
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man fibroblasts and human astrocytes when expressed in
specific combinations (Pereira et al., 2014; Rivetti di Val
Cervo et al., 2017; Torper et al., 2013). Here, we tested the
effect of these additional DA fate determinants when con-
verting hGPCs to DA neurons (Figure 4A). Gene expression
analysis 3 weeks after initiation of reprogramming showed
that the addition of Otx2 to the original reprogramming
cocktail did not add any beneficial effects in terms of re-
programming efficiency and DA phenotype (Figures S5A–
S5C). The NeuroD1, Ascl1, Lmx1a, and mir218
(NeAL218) factor combination used in Rivetti di Val Cervo
et al. (2017) resulted in a comparable number of TH+ iDANs
and a similar gene expression profile as ALN + shREST re-
programmed cells, when assessed 3 weeks after transgene
activation (Figures S5D and S5E). In contrast, when Foxa2
was added to the initial cocktail (Figures 4B and 4C), the
gene expression analysis showed a higher endogenous
expression of the midbrain DA genes LMX1B (p =
0.0098), EN1 (p = 0.0001), and OTX2 (p = 0.0075) (Fig-
ure 4E). The addition of Foxa2 also resulted in increased
expression of the DA synthesis-related enzyme DDC (p <
0.0001) (Figure 4E), which was confirmed at the protein
level using immunocytochemistry (Figures 4F, 4G, and
S5F). At the same time, the proportion of TH+ neurons in
the 3-weeks culture did not differ significantly between
the ALN + shREST and ALN + Foxa2 + shREST transduced
cells (p = 0.224 as determined using an unpaired, two-tailed
t test and see Figure 5G). We also tested the NeAL218 and
ALN + Foxa2 + shREST factor combinations in the fetal
hGPCs and confirmed that while both these combinations
successfully generate iNs with a DA phenotype (Figures
S5G and S5H), the addition of Foxa2 again resulted in a
higher expression of LMX1B and DDC (Figure S5I).
Although hESC-derived hGPCs could be reprogrammed
into TAU+ iNs at 3 weeks after transgene activation with
an efficiency of 35%–40%, the relative proportion of TH+
iDANs remained low at this point (Figures 5A, 5B, and
5G). Gene expression analysis at this time point suggested
that other subtypes of neurons, such as glutamatergic and(B and C) TH+/TAU+ neurons generated with either ALN + shREST (B) or
from hESC-derived hGPCs.
(D) No TH+/TAU+ neurons are generated when the hESC-derived hGPC
(E) qPCR analysis of gene expression of iDANs 3 weeks after transgene
or ALN + Foxa2 + shREST.
(F and G) Immunocytochemical analysis of DDC and FOXA2 in cells rep
(G).
Data are presented as means ± SEM, and all data points have been visu
independent experiment (n = 9–12 for ALN + shREST; n = 6–7 for ALN
The gene expression levels for the conditions ALN + shREST and ALN
0.01 (p = 0.0098 for LMX1B, p = 0.0075 for OTX2); ***p < 0.001 (p =
Figure S5.GABAergic neurons, could also be present in the cultures
(Figure S6A). To investigate if the proportion of TH+ neu-
rons increases with time, wemaintained the ALN + shREST
and ALN + Foxa2 + shREST reprogrammed cells in long-
term culture, with either maintained transgene expression
(i.e., continued dox administration to themedium) or with
transgene de-activation via dox withdrawal after 3 weeks
(Figure 4A). Quantification at day 50 and day 100 (24 and
74 days after dox withdrawal, respectively) showed that
the proportion of TH+ iDANs in both culture conditions
was significantly increased over time, reaching as high as
50%, while the neuronal content did not change signifi-
cantly from the 3-week time point (Figures 5C–5G). The ob-
servations that the total number of cells did not change
(Figure S6F) and the neuronal proportions were compara-
ble between time points, while the relative proportion of
TH+ neurons increased, suggested that the converted cells
undergo progressive DA maturation; this was later
confirmed with electrophysiology (see Figure 6). Interest-
ingly, when ALN + shREST was used for conversion, a
high number of TH+ iDANs was generated both with and
without dox withdrawal (Figures 5E and S6B), but when
Foxa2 was added to the reprogramming mix, a high num-
ber of TH+ iDANs was only observed when dox was with-
drawn from the medium (Figures 5F and S6C). This indi-
cates that while the addition of Foxa2 to the conversion
factor cocktail increased DA-specific conversion initially,
maintenance of the exogenous Foxa2 expression had a
negative effect of the subtype identity and maturation of
the iDANs. Indeed, the unphysiologically high and/or pro-
longed expression of Foxa2 seemed to directly interfere
with the expression of TH, since none of the cells that
were strongly positive for FOXA2 co-labeled with TH, and
the TH+ neurons only showed weak nuclear labeling of
FOXA2 by immunocytochemistry (Figure S6D). Immuno-
cytochemistry confirmed the expression of the mature
neuronal- and DA neuron markers SYN1, VMAT2, and
ALDH1A1 in long-term cultures of ALN + shREST reprog-
rammed cells (Figures 5H–5J), and at this late time point,
DDC+ neurons were present in equal quantities in ALN +ALN + Foxa2 + shREST (C) 3 weeks after transgene activation starting
s are kept for 3 weeks in parallel in glial medium.
activation comparing cells reprogrammed with either ALN + shREST
rogrammed using either ALN + shREST (F) or ALN + Foxa2 + shREST
alized in the graphs. Each data point represents a replicate from an
+ Foxa2 + shREST; n = 4–5 for CNTRL-NDIFF; n = 6–8 for CNTRL-GM).
+ Foxa2 + shREST were compared using a Mann-Whitney test; **p <
0.0001 for EN1, p < 0.0001 for DDC). Scale bars: 50 mm. See also
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Figure 5. Progressive Subtype-Specific Maturation of the iDANs over Time
(A, C, and E) The proportion of TH+ iDANs increase when doxycycline is withdrawn after 3 weeks and the ALN + shREST reprogrammed
neurons are kept in culture for 50 days (C) and 100 days (E), compared with the 3-week time point (A).
(B, D, and F) The proportion of TH+ iDANs increases when doxycycline is withdrawn after 3 weeks and the ALN + Foxa2 + shREST re-
programmed neurons are kept in culture for 50 days (D) and 100 days (F), compared with the 3-week time point (B).
(G) Quantifications of neuronal proportion and TH+ neuronal proportion over time. TH+ neuronal proportion (ALN + shREST): 3 weeks, 3.6%
± 1.0%, n = 7; 50 days, 31.4% ± 5.6%, n = 2; 100 days, 53.9% ± 8.3%, n = 3. TH+ neuronal proportion (ALN + Foxa2 + shREST): 3 weeks,
1.8% ± 0.8%, n = 5; 50 days, 34.5% ± 3.6%, n = 2; 100 days, 50.2% ± 4.9%, n = 3. Neuronal proportion (ALN + shREST): 3 weeks, 41.8% ±
5.0%, n = 7; 50 days, 49.8% ± 18.1%, n = 2; 100 days, 45.8% ± 8.0%, n = 3. Neuronal proportion (ALN + Foxa2 + shREST): 3 weeks, 34.3% ±
5.0%, n = 5; 39.2% ± 11.7%, n = 2; 100 days, 38.4% ± 14.2%, n = 3.
(H–J) The generated iDANs are positive for SYN1 (H), VMAT2 (I), and ALDH1A1 (J).
(K and L) TH+/DDC+ double-labeled cells are observed in long-term cultures of both ALN + shREST (K) and ALN + Foxa2 + shREST (L) re-
programmed cells. White arrows indicate examples of double-labeled cells.
(legend continued on next page)
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(Figures 5K, 5L, and S6G).
The Reprogrammed iDANs Become Functionally
Mature
To better characterize the maturation and functional prop-
erties of iDANs at later stages of reprogramming, we
focused on ALN + shREST and ALN + Foxa2 + shREST
with dox withdrawal from the medium after the first
3 weeks of conversion. Comparing the gene expression
profile of the reprogrammed iDANs at 3 weeks with the
expression profile at later time points (day 50 and day
100) showed that while the endogenous expression of
the DA progenitor markers LMX1A, FOXA2, and LMX1B
decreased over time, the expression of the post-mitotic
DA markers TH and NURR1 increased (Figure S6E).
To assess the electrophysiological properties of iDANs
that had been reprogrammed from hESC-derived hGPCs,
whole-cell patch-clamp recordings were performed at
day 60 and day 100 of reprogramming. At these time
points, no detectable differences in intrinsic membrane
properties were observed between the groups (see Table
S3). After 60 days (34 days after dox withdrawal), cells re-
programmed with ALN + shREST showed induced APs in
higher proportion (9/24 cells firing), compared with
ALN + Foxa2 + shREST (1/12 cells firing; Figure 6A). At
day 100, the iDANs had matured further, with APs in
21/45 cells for ALN + shREST and 9/45 cells for ALN +
Foxa2 + shREST. There was a trend of a greater number
of cells displaying multiple APs in ALN + shREST condi-
tion compared ALN + Foxa2 + shREST condition (Figures
6A and 6B). The induced APs could be selectively blocked
by tetrodotoxin (TTX, 1 mM) (Figure S6H). Both ALN +
shREST and ALN + Foxa2 + shREST iDANs displayed
fast-inactivated inward and outward currents character-
istic of sodium and delayed-rectifier potassium currents
(Figure 6C and Table S3) as well as spontaneous postsyn-
aptic activity indicative of synaptic integration (Figures
6D and S6I, d100: n = 13/43 for ALN + shREST and 10/
41 for ALN + Foxa2 + shREST). iDANs from both condi-
tions also showed the presence of spontaneous firing at
resting membrane potential (Figure 6E) and repetitive
APs at small current injections (Figure 6F), indicative of
a DA phenotype. The proportion of cells exhibiting spon-
taneous firing was 11% for ALN + shREST and 8% ALN +
Foxa2 + shREST at day 60 with a higher proportion at dayData are presented as means ± SEM and all data points have been visu
independent experiment (n = 7 for ALN + shREST at the 3-week time po
both conditions at the D50 time point and n = 3 for both conditions at
cells at the 3-week time point was compared with the late time points
***p < 0.001 (p < 0.0001 for TH+ cells in ALN + shREST, p < 0.0001 for
ALN + shREST, p = 0.6637 for TAU+ cells in ALN + Foxa2 + shREST). S100 for the ALN + shREST group (37%). Moreover, the
iDANs also showed repetitive AP at small current injec-
tions already at day 60 (11% for ALN + shREST and 10%
for ALN + Foxa2 + shREST, Figure 6F), a feature that was
further increased in ALN + shREST condition at day 100
(ALN + shREST 37%, ALN + Foxa2 + shREST 10%).
Taken together, these results show that hESC-derived
hGPCs convert into functional neurons with DA properties
that achieve mature profiles after long-term culture.DISCUSSION
The potential of cell replacement therapy as a means of
treating PD has been established through clinical trials us-
ing human fetal ventral midbrain tissue (Barker et al.,
2015), and efforts are currently underway with the aim of
assessing hPSCs as a source of transplantable DA progeni-
tors (Barker et al., 2017; Doi et al., 2020; Schweitzer et al.,
2020). In vivo direct reprogramming of resident glia into
DA neurons is similarly based onDA neuronal replacement
but circumvents cell transplantation, as the new neurons
are generated by reprogramming resident cells in situ
(Grealish et al., 2016; Vignoles et al., 2019).
Several studies have shown that it is possible to obtain
subtype-specific and functional neurons via transcription
factor-mediated reprogramming of mouse GPCs in vivo
(Guo et al., 2014; Heinrich et al., 2014; Pereira et al.,
2017; Torper et al., 2015) or via inhibition of PTB (Qian
et al., 2020), but analogous studies using human cells
have been lacking. In this study, we therefore established
an in vitro model of direct neural conversion from hESC-
derived hGPCs. This model has a distinct advantage over
existing models that use fetal tissue-derived glia, since gen-
eration from stem cells of highly expandable hGPCs pro-
vides us with the opportunity to reproducibly assess the
biology of neuronal reprogramming from human cells,
while doing so at scale using a preferentially permissive
but otherwise scarce cell type.
Once established, this hPSC-based experimental model
system for hGPC reprogramming studies allowed us to
conduct detailed in vitro studies of the timeline of reprog-
ramming, the effect of different reprogramming factors,
and the phenotypic profile and electrophysiological prop-
erties of the reprogrammed iDANs. Using several combina-
tions of transcription factors, including ALN, ALN + Foxa2,alized in the graphs. Each data point represents a replicate from an
int; n = 5 for ALN + Foxa2 + shREST at the 3-week time point; n = 2 for
the D100 time point). In (G), the proportion of TAU+ and TAU+/TH+
day 50 and day 100 combined using an unpaired, two-tailed t test.
TH+ cells in ALN + Foxa2 + shREST); n.s. (p = 0.5307 for TAU+ cells in
cale bars: 50 mm. See also Figure S6.
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Figure 6. hESC-Derived hGPCs Reprogrammed iDANs Become Functionally Mature
(A) Graph showing the number of cells exhibiting multiple, single, or no AP responses evoked by current steps at 60 and 100 days after
reprogramming start with ALN + shREST and ALN + Foxa2 + shREST.
(B) Representative trace of voltage responses from the whole-cell patch-clamp technique showing multiple induced APs in cells re-
programmed with ALN + shREST (left, purple) ALN + Foxa2 + shREST (right, green).
(C) Inward sodium current peak (left) and outward potassium current (right) plotted against voltage steps of cells reprogrammed with
ALN + shREST (purple) and ALN + Foxa2 + shREST (green).
(D) Spontaneous postsynaptic currents in an ALN + shREST reprogrammed neuron.
(E) Spontaneous firing at resting membrane potential in an ALN + shREST reprogrammed neuron.
(F) Repetitive induced AP at small current injections in an ALN + shREST reprogrammed neuron.
See also Figure S6.
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cessfully reprogram human fibroblasts and astrocytes into
DA neurons (Caiazzo et al., 2011; Rivetti di Val Cervo
et al., 2017; Torper et al., 2013), we confirmed that the
same factors could successfully reprogram hGPCs as well.
Knockdown of REST, which acts to suppress neuronal iden-
tity, has previously been shown to greatly increase the effi-
ciency of neuronal reprogramming, starting from adult hu-
man fibroblasts (Drouin-Ouellet et al., 2017a). REST is
expressed by both GPCs and differentiating astrocytes,
where it restricts the neuronal program, and its knockdown
has been shown to result in an induction of neuronal genes
(Dewald et al., 2011; Kohyama et al., 2010; Liu et al., 2019).
Accordingly, the combined knockdown of REST together
with ALN resulted in iNs with a DA neuron profile when re-
programming hGPCs. The addition of Foxa2 to the reprog-
ramming cocktail resulted in a stronger endogenous
expression of midbrain DA progenitor genes, such as
OTX2, LMX1B, and EN1 after 3 weeks of conversion, but
sustained expression directly interfered with the acquisi-
tion of a TH+ phenotype.10 Stem Cell Reports j Vol. 15 j 1–14 j October 13, 2020Long-term assessment of the reprogrammed iDANs es-
tablished that the cells were stably converted and did not
rely on continuous expression of conversion factors.
Phenotypic and functional assessment using patch-clamp
electrophysiology revealed that the reprogrammed neu-
rons matured over time, resulting in an approximately
15-fold increase of TH+ iDANs in the culture and an adop-
tion of functional electrophysiological properties in line
with a DA neuron identity. However, just as when fibro-
blasts are converted to DA neurons (Caiazzo et al., 2011;
Pfisterer et al., 2011; Torper et al., 2013), not all of the re-
programmed cells adopt a DA neuron identity. In this
study, we also detected expression of markers suggesting
the presence of other subtypes of neurons, including
GABAergic and glutamatergic neurons, and the exact
phenotype of these neurons remains to be established.
Furthermore, while glial markers are rapidly suppressed in
these cells, not all glia convert into neurons. This may be
due to a technical limitation, in that the conversion factors
are delivered on separate vectors, with the result that not all
cells are transduced to co-express all factors, and the
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transduced cell population. Going forward, such incom-
pletely transduced or reprogrammed cells will need to be
removed before iDANs can be evaluated for clinical use.
The reprogrammed neurons matured functionally after
long-term culture. However, even at the late time points,
a proportion of the neurons were not functionally mature.
This can be due to initial asynchrony in reprogramming,
culture conditions that may not be ideal for maturation,
or insufficient support of mature cells in 2D cultures, and
future studies are needed to develop culture conditions
more optimal for long-term maintenance of functionally
mature cells.
Together, these observations suggest that our hPSC-based
system for hGPC reprogramming is effective at reproduc-
ibly producing iDANs, while providing a platform for
broader studies aiming at converting hGPCs into other sub-
types of neurons as well, because it provides scalable popu-
lations of reprogramming-permissive human cells. In the
current study, we identified combinations of transcription
factors thatwere able to successfully convert both fetal- and
stem cell-derived hGPCs directly into functional iDANs.
Thus, this study provides an important proof of principle
that hPSC-derived hGPCs comprise especially permissive
targets for efforts aimed at converting endogenous cells
into context-appropriate neurons, in both the diseased
and damaged brain, including DA neuronal replacement
in PD.EXPERIMENTAL PROCEDURES
hESC Culture and Generation of Human GPCs from
hESCs
Glial differentiation was initiated from two different hESC lines:
RC17 (RCe021-A, p26-30) and HS1001 (KIe055-A, p8). The undif-
ferentiated hESCs were maintained on LN521 (0.5 mg/cm2; Bio-
lamina)-coated tissue culture plates in iPS Brew XFmedium (Stem-
MACS; Milteny) and passaged weekly with EDTA (0.5 mM).
For differentiation of hESCs into hGPCs, the protocol developed
in the Goldman lab (Wang et al., 2013) was employed with some
minor modifications. For detailed information, see Supplemental
Experimental Procedures.Culturing of Human Fetal GPCs
Human fetal brain tissue from aborted fetuses (20 weeks gesta-
tional age) was obtained with donor consent and under protocols
approved by theUniversity of Rochester-StrongMemorial Hospital
Research Subjects Review Board. The isolation of glial progenitors
from the fetal brain tissue was performed as previously described
(Benraiss et al., 2016). The cells were subsequently grown on sus-
pension plates (Greiner Bio-One) in DMEM/F12/N1 medium sup-
plemented with bFGF (10 ng/mL) and 2% PD-FBS at 2.0 3 105
cells/mL and passaged every 10–14 days.Viral Vectors and Transduction
Doxycycline-regulated lentiviral vectors expressing mouse cDNA
and the Tet-On trans-activator (FuW.rtTA-SM2; Addgene), have
been described previously (Pereira et al., 2014; Pfisterer et al.,
2011; Rivetti di Val Cervo et al., 2017). REST shRNA sequences
were either expressed in lentiviral constructs under control of a
U6 promotor or expressed in a single doxycycline vector construct
containing REST shRNA sequences and Ascl1 cDNA. Third-genera-
tion lentiviral vectors were produced as previously described (Zuf-
ferey et al., 1997) and titrated by quantitative PCR analysis (Geor-
gievska et al., 2004). All viruses used in this study titered between
3 3 108 and 8 3 109. Both fetal- and hESC-derived hGPCs were
quite sensitive to the viral transduction, resulting in relatively
high levels of cell loss during the early stage of reprogramming
compared with starting from fibroblasts for example. This effect
showed some cell-batch dependency, and the later inclusion of
additional reprogramming factors to the conversion cocktail re-
sulted in an increased viral load, which in general resulted in
slightly higher cell death. Therefore, conversion of fetal- and
hESC-derived hGPCs required lower multiplicities of infections
(MOI; 0.5–2) compared with studies using fibroblasts (Drouin-
Ouellet et al., 2017a).Direct Neuronal Conversion of Human GPCs
Fetal hGPCs or hESC-derived hGPCs were seeded in their normal
culturingmediumon plates that had been serially coatedwith poly-
ornithine (PO), laminin (Lam), and fibronectin (FN), at a density of
50,000 cells/cm2. For electrophysiological analysis, the cells were
seededonto PO/Lam/FN-coated coverslips that had been pre-treated
according to Richner et al. (2015). One day after seeding, the cells
were transduced at an MOI of 0.5–1 per vector (fetal hGPCs) or
MOI of 1–2 per vector (hESC-derived hGPCs), and the medium
was changed the next day to remove the viral vectors. Doxycycline
(2 mg/mL) was added to the culture medium 5 days after transduc-
tion to activate the transgenes, and 2 days later the medium was
switched to neural differentiation medium (NDiff227; Takara-Clon-
tech) containing the following small molecules (SMs): CHIR99021
(2 mM; Axon), SB-431542 (10 mM; Axon), noggin (0.5 mg/mL; R&D
Systems), LDN-193189 (0.5 mM; Axon), and valproic acid sodium
salt (VPA 1 mM; Merck Millipore); and the following growth factors
(GFs): LM-22A4 (2 mM; R&D Systems), GDNF (2 ng/mL; R&D Sys-
tems), NT3 (10 ng/mL; R&D Systems), and db-cAMP (0.5 mM;
Sigma). Two-thirds of the medium was changed every 2–3 days.
Two weeks post transduction, the SMs were withdrawn from the
neuronal differentiation medium, and the medium was supple-
mented with only the GFs until the end of the experiment. For
long-term assessment of the maturation of the reprogrammed cells,
doxycycline was either kept in the medium until the end or with-
drawn 3 weeks post transgene activation.
Immunocytochemistry
The cells were fixed in 4%paraformaldehyde solution for 15min at
room temperature (RT) before staining. The cells were pre-incu-
bated in a blocking solution containing 0.1 M phosphate buffered
salinewith potassium (KPBS) + 0.1%Triton + 5% serum (of second-
ary antibody host species) for 1–3 h before the primary antibody
solution was added (see Table S4). The cells were incubated withStem Cell Reports j Vol. 15 j 1–14 j October 13, 2020 11
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the following day before adding the secondary antibody solution
containing fluorophore-conjugated antibodies (1:200; Jackson Im-
munoResearch Laboratories) and DAPI (1:500). The cells were
incubated with the secondary antibodies for 2 h at RT and finally
washed with KPBS.qRT-PCR
RNA was isolated from the cells using the RNeasy Micro kit (QIA-
GEN). Reverse transcription was performed with a Maxima First
Strand cDNA Synthesis Kit for RT-qPCR (Thermo Fisher Scientific),
using 0.2–0.5 mg of RNA per sample. The cDNA (1 mL) was pipetted
together with LightCycler 480 SYBR Green I Master (5 mL; Roche)
and relevant primers (4 mL, see Table S5; Integrated DNA Technolo-
gies) using the Bravo pipetting robot instrument (Agilent) and
analyzed by qRT-PCR on a LightCycler 480 II instrument (Roche) us-
ing a 403 cycle two-step protocol with a 60C, 1-min annealing/
elongation step and a 95C, 30-s denaturation step. All samples
were run in technical triplicates, and the average CT values were
used for calculating the relative gene expression using the DDCT
method. All fold changes were calculated as the average fold change
based on two different housekeeping genes (b-actin and GAPDH)
relative to the starting cells before conversion was initiated.High Content Analysis
Cells were imaged at 103 magnification using a Cellomics Array
Scan VTI HCS reader (Thermo Fisher Scientific). The total number
of cells per well positive for DAPI, TAU, and THwere quantified us-
ing HCS Studio 3.0 Scan software (Thermo Fischer), which is an
automated process enabling unbiased assessment of fluorescence
intensity and distribution. Applying the program ‘‘Target Activa-
tion,’’ data from 289 fields were collected from the entire well (cor-
responding to an average number of 21,049 cells). TAU+ neurons
were defined as cells containing a DAPI+ nuclei and a Cy2-TAU
average fluorescence intensity above background of internal nega-
tive control cells. TH+ neurons were defined as TAU+ neurons with
a Cy3-TH average fluorescence intensity above background of in-
ternal negative control cells.Statistical Analysis
All data are expressed asmeans ± standard error of themean (SEM).
For gene expression analysis and cellomics analysis, n represent
replicates from independent experiments. A Shapiro-Wilk
normality test was used to assess the normality of the distribution,
and parametric or nonparametric tests were performed
accordingly.
For comparing the proportions of CD140+ cells before and after
cryopreservation in Figure 2D, a paired, two-tailed t test was
used. For qPCR data related to Figure 4E, outliers were identified us-
ing Grubbs’s test and removed from the dataset. Since normality
could not be proven, a Mann-Whitney test was used to compare
the gene expression levels of ALN + shREST and ALN + Foxa2 +
shREST. To compare the number of TAU+ and TAU+/TH+ at early
and late time point in Figure 5G, the 3-week time point was
compared with day 50 and day 100 combined using an unpaired,
two-tailed t test. In Figures S3F and S3G, correlations were assessed12 Stem Cell Reports j Vol. 15 j 1–14 j October 13, 2020using Pearson’s r. In Figures S5F and S6H, the proportions of DDC+
cells were compared using unpaired, two-tailed t tests.
Statistical analyses were conducted using GraphPad Prism 8.0.
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Supplemental Information can be found online at https://doi.org/
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Fig S1 Characterization of fetal hGPCs. Related to Figure 1.
(A-C) Immunocytochemical characterization of glial and neuronal 
markers in three different passages (P2, P5 and P12) of fetal hGPCs, 
showing stainings of GFAP/PDGFRα (A), TAU/MAP2(a+b+c) (B) and 
MAP2(a+b)/TH (C). 
(D) After 1 weeks of transgene activation, induced TH+/MAP2+ neurons 
appear in the culture and the number of GFAP+ cells decrease. 
(E) Quantifications of neuronal proportion (56.3 ± 5.6%) and TH+ neu-
ronal proportion (1.25 ± 0.69%) after three weeks of reprogramming. 
(F and G) GFAP+ and PDGFRα+ hGPCs kept in glial medium (F) or neu-
ronal conversion medium (G) for 3 weeks in parallel to reprogrammed 
cells. In Fig S1E, data are presented as mean ± SEM and all data points 
have been visualized in the graphs. Each data point represents a repli-
catefrom an independent experiment. Scale bars: 100 μm.
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Fig S2 Characterization of hESC-derived hGPCs. Related to Figure 2.
(A) Flow cytometry analysis of the expression of CD140 and CD44 over time and following cryopreservation of hGPCs at day 
190 of differentiation +15 days post thaw. 
(B-E) Immunocytochemical characterization of glial markers in hESC-derived hGPCs at different stages and before and after 
cryopreservation shows cells positive for GFAP, OLIG2 and SOX10 (B), GFAP, OLIG2 (C), PDGFRα and O4 (D), and NFIA, but 
not NGN2 (E).
(F) Immunocytochemical characterization of MAP2(a+b+c) and TAU in hESC-derived hGPCs at different stages and before and 
after cryopreservation
(G-H) Cultures of hESC-derived hGPCs contain rare TH+ cells. These TH+ cells are of a glial identity since they do no not co-label 
with MAP2 (a+b), TAU or NEUN (G, indicated with a blue arrows), but instead co-label with GFAP and PDGFRα (H, indicated 
with white arrows). Scale bars: (A–C, F, H) 100 μm; (D,G ) 50 μm.
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Fig S3 Direct neuronal reprogramming of hESC-derived hGPCs. Related to Figure 2.
(A) After 1 week of transgene activation, induced TH+/MAP2+ neurons appear in the culture.
(B) 3 weeks after transgene activation, GFAP+ and PDGFRα+ cells completely disappear from the culture. 
(C) hESC-derived hGPCs kept in parallel in neuronal conversion medium for 3 weeks do not give rise to any TH+/TAU+ neurons.
(D and E) GFAP+ and PDGFRα+ cells are maintained when the hESC-derived hGPCs are kept in neuronal conversion medium (D) 
and glial medium (E).
(F) Days in culture prior to the reprogramming does not affect the induction of TH or SYN1 in the reprogrammed cultures. 
(G) The variable proportion of the different progenitor types in different starting cell batches affects the induction of SYN1, but 
not of TH, in the reprogrammed cells. 
In Fig S3F and S3G, each data point represents a replicate from an independent experiment and correlations have been assessed 
using Pearson’s r. 
Scale bars: (A) 50 μm; (B-E) 100 μm.
Fig S4. FACS sorting of CD140+ cells for neuronal reprogramming. Related to Figure 3.
(A-C) FACS plots showing the gating strategy for sorting CD140+ single cells and reanalysis plot 
to assess the stringency of the strategy. Unstained cells are shown in (A), CD140-stained cells are 
shown in (B) and re-analyzed CD140-stained cells are shown in (C). 
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Fig S5 Assessment of factor combinations for direct conversion to a DA fate. Related to Figure 4.
(A) qPCR analysis of reprogrammed cells 3 weeks after transgene activation comparing cells reprogrammed with ALN+shREST, 
or with ALN+shREST together with Otx2 and/or Foxa2.
(B-D) TH+/TAU+ cells generated with either ALN+Otx2+shREST (B), ALN+Otx2+Foxa2+shREST (C), or NeAL218 (D) 3 weeks 
after transgene activation starting from hESC-derived hGPCs.
(E) qPCR analysis of reprogrammed cells 3 weeks after transgene activation comparing cells reprogrammed with either  
ALN+shREST or NeAL218 starting from hESC-derived hGPCs.
(F) Quantification of the proportion of DDC+ cells in cultures reprogrammed with either ALN+shREST or ALN+Foxa2+shREST.
(G-H) Fetal primary hGPCs can be reprogrammed into TH+/TAU+ cells using ALN+Foxa2+shREST (F) and NeAL218 (G).
(I) Addition of Foxa2 to the reprogramming ALN+shREST cocktail results in a higher expression of LMX1B and DDC in fetal 
hGPCs.
In Fig S5A, S5E-F and S5I, data are presented as mean ± SEM and all data points have been visualized in the graphs. For the gene 
expression data in Fig S5A, S5E and S5I, each data point represents a replicate from an independent experiment. (S5A: n=2; S5E 
n=5 for ALN+shREST; n=3 for NeAL218; n=3 for CNTRL – GM; S5I: n=5 for ALN+shREST; n=3 for ALN+Foxa2+shREST). 
The data points displayed for qPCR data for ALN+shREST, ALN+Foxa2+shREST and CNTRLs in Fig S5A and S5E are also 
included of the comparison of ALN+shREST and ALN+Foxa2+shREST in Fig 4E. The data points displayed for qPCR data of 
LMX1B for ALN+shREST in Fig S5I are also incuded in Fig 1F. In Fig S5F, the proportions of DDC+ cells were calculated from 
446 (ALN+shREST) and 449 (ALNF+shREST) cells in 4 randomly sampled fields from one experiment. The proportions of 
DDC+/DAPI+ for the conditions ALN+shREST and ALN+FOXA2+shREST were compared using an unpaired, two-tailed, t-test; 
*p<0.05 (p=0.0124). Scale bars: (B-D) 100 μm; (G-H) 50 μm.
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Fig S6 Phenotypic maturation of iDANs. Related to Figures 5 and 6.
(A) qPCR analysis of different neuronal markers in ALN+shREST and ALN+Foxa2+shREST reprogrammed cells 3 weeks after 
transgene activation.
(B-C) Maintained doxycycline administration does not affect the proportion of TH+ iDANs  when cells are reprogrammed with 
ALN+shREST (B) but results in a lower proportion on TH+ neurons when the cells are reprogrammed with ALN+Foxa2+shREST 
(C). 
(D) Cells that show a strong labeling of FOXA2 are not TH+. White arrow in right panel indicates a TH+ cell with weak nuclear 
labeling of FOXA2.
(E) Gene expression analysis at late timepoint relative to the expression of each gene at the early 3-week timepoint.
(F) Quantification of the proportion of DDC+ cells in cultures reprogrammed with either ALN+shREST or ALN+Foxa2+shREST 
after 100 days. 
(G) Quantifications of the numbers of cells per well in repgrogrammed cutures after 3 weeks, 50 days and 100 days.
(H) Representative trace of voltage responses from whole cell patch clamp technique showing induced AP (purple) selectively 
blocked by tetrodotoxin (TTX, black).
(I) Pie chart showing different number of cells exhibiting spontaneous postsynaptic activity at 60 and 100 days after reprogram-
ming start with ALN+shREST (left) and ALN+Foxa2+shREST (right). 
Data are presented as mean ± SEM. In Fig S6A, each data point represents a replicate from an independent experiment (n=9-11 
for ALN+shREST; n=7 for ALN+Foxa2+shREST; n=3-5 for CNTRL – NDIFF; n=6-8 for CNTRL – GM). The gene expres-
sion levels for the conditions ALN+shREST and ALN+Foxa2+shREST were compared using a Mann-Whitney test;  **p<0.01 
(p=0.0079 for SERT). In Fig S6E gene expression data was collected from 2 independent experimental replicates per time point 
and the expression is described relative to the early time point. In Fig S6G, the proportions of DDC+ cells were calculated from 
717 (ALN+shREST) and 1,249 (ALN+Foxa2+shREST) cells in 6-7 randomly sampled fields from one experiment. The propor-
tions of DDC+/DAPI+ for the conditions ALN+shREST and ALN+Foxa2+shREST were compared using an unpaired, two-tailed, 
t-test (p=0.0901). Scale bars: 50 μm.
Table S1: Summary of electrophysiological properties of fetal hGPCs. Related to Figure 1. 
 
Intrinsic Properties ALN + shREST 
Resting membrane potential (mV) d80-120= -30.41 ± 1.51 
Cell capacitance (pF) d80-120 = 17.94 ± 1.42 
 
 
Table S2: Cell batches used to as starting cells for reprogramming experiments. Related to Figure 2. 
 
hESC-line hGPCs 
Batch ID 
Days in 
culture 
Total 
CD140+ 
cells 
Total CD44+ 
cells 
CD140+/ 
CD44+ 
CD140+/ 
CD44- 
CD44+/ 
CD140- 
RC17 LU7 165 64.9% 14.7% 8.7% 48.9% 3.7% 
RC17 LU3 203 65.2% 28.6% 23.7% 41.4% 0.6% 
RC17 LU3 212 65.2% 28.6% 23.7% 41.4% 0.6% 
RC17 LU13 238 59.9% 50.8% 52.8% 12.5% 7.2% 
RC17 LU16 202 32.4%  23.8% 13.7% 19.8% 10.9% 
HS1001 LU27 195 66.7% 3.2% 3.8% 61.2% 0.1% 
RC17 LU3 239 60.9% 20.1% 18.3% 42.7% 0.2% 
RC17 LU6 271 60.5% 10.0% 10.2% 50.6% 0.2% 
 
 
Table S3: Summary of electrophysiological properties of hESC derived hGPC. Related to Figure 6. 
 
Intrinsic Properties ALN  ALNF P (between groups) 
Resting membrane 
potential (mV) 
d60 = -28.64 ± 1.2  
d100 = -28.14 ± 1.1 
d60 = -25.58 ± 1.5 
d100 = -32.88 ± 0.8 
>0.999 
0.086 
Cell capacitance (pF) d60 = 14.81 ± 1.3  
d100 = 14.46 ± 1.2 
d60 = 10.36 ± 1.0  
d100 = 14.78 ± 1.1 
0.471 
>0.999 
Input resistance (MW) d60 = 3469 ± 476.0 
d100 = 3347 ± 207.6 
D60 = 4928 ± 402.2 
D100 = 3476 ± 377.6 
0.247 
>0.999 
 
There were no significant differences between the groups or times post-conversion (d60 vs d100) in any of the 
intrinsic properties. mV = millivolt, pF = picofarad, MW = Mega Ohm. One-way ANOVA with Bonferroni 
multiple comparison post hoc test was used for statistical comparison.  
Table S4: Primary antibodies used in this study. Related to Figure 1-5. 
 
Antigen Species Company (cat. no.) Dilution 
ALDH1A1 Rabbit Abcam (ab24343) 1:200 
DDC Rabbit Merck Millipore (AB1569) 1:500 
FOXA2 Goat R&D systems (AF2400) 1:500 
GFAP Mouse Biolegend (SMI 21) 1:500 
MAP2 Mouse Sigma Aldrich (M1406) 1:500 
MAP2 Rabbit Millipore (AB5622) 1:500 
NEUN Rabbit Millipore (ABN78) 1:500 
OLIG2 Rabbit Neuromics (RA25081) 1:500 
O4 Mouse Merck Millipore (MAB345) 1:100 
PDGFRα Rabbit Cell Signaling Technology (5241S) 1:300 
SOX10 Goat R&D systems (AF2864) 1:25 
SYNAPSIN 1 Rabbit Merck Millipore (AB1543) 1:200 
TAU (HT7) Mouse Thermo Fisher (MN1000) 1:500 
TH Rabbit Merck Millipore (AB152) 1:1,000 
TH Sheep Merck Millipore (AB1542) 1:1,000 
VIMENTIN Chicken Merck Millipore (AB5733) 1:2,000 
VMAT2 Rabbit Sigma Aldrich (AB1598P) 1:200 
 
  
Table S5: Primers used for qRT-PCR analysis. Related to Figure 1 and 4. 
 
Gene Full gene name Primer sequence (fwd/rev) 
ACTB  Beta-actin  CCTTGCACATGCCGGAG  
GCACAGAGCCTCGCCTT  
CHAT  Choline O-acetyltransferase TCCAACGAGGACGAGCGTTTGC 
CGAGTCCCGGTTGGTGGAGTCT 
DDC  DOPA decarboxylase GGGGACCACAACATGCTGCTCC  
AATGCACTGCCTGCGTAGGCTG 
DAT (SLC6A3) Dopamine transporter CACTGCAACAACTCCTGGAA 
AAGTACTCGGCAGCAGGTGT 
EN1 Engrailed 1  CGTGGCTTACTCCCCATTTA  
TCTCGCTGTCTCTCCCTCTC  
FOXA2 Forkhead box A2 CCGTTCTCCATCAACAACCT 
GGGGTAGTGCATCACCTGTT 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase  
TTGAGGTCAATGAAGGGGTC  
GAAGGTGAAGGTCGGAGTCA  
GFAP Glial fibrillary acidic protein TCATCGCTCAGGAGGTCCTT 
CTGTTGCCAGAGATGGAGGTT 
LMX1A (UTR) 
 
LIM homeobox transcription 
factor a 
CGCATCGTTTCTTCTCCTCT  
CAGACAGACTTGGGGCTCAC  
LMX1B LIM homeobox transcription 
factor b 
CTTAACCAGCCTCAGCGACT  
TCAGGAGGCGAAGTAGGAAC  
NCAM1 Neural cell adhesion molecule 1 GTCAGAGGCCACCGTCAACGTG 
CTTCCCCCTCCCGGAACTCCTG 
 NR4A2 (NURR1, intron-
spanning) 
Nuclear receptor subfamily 4, 
group A, member 2 
CAGGCGTTTTCGAGGAAAT 
GAGACGCGGAGAACTCCTAA 
OTX2 Orthodenticle homeobox 2 ACAAGTGGCCAATTCACTCC  
GAGGTGGACAAGGGATCTGA  
PDGFRA Platelet derived growth factor 
receptor alpha 
CCTTGGTGGCACCCCTTAC 
TCCGGTACCCACTCTTGATCTT 
PITX3 Paired-like homeodomain 3 GGAGGTGTACCCCGGCTACTCG 
GAAGCCAGAGGCCCCACGTTGA 
SERT (SLC6A4) Serotonin transporter TGGACCCTCCATTCCACGTCCC 
GTCCTGGAGCCCCTTAGACCGG 
SYP Synaptophysin ACCTCGGGACTCAACACCTCGG 
GAACCACAGGTTGCCGACCCAG 
SYN1 Synapsin 1 CCCGTGGTTGTGAAGATGGGGC 
TGCCACGACACTTGCGATGTCC 
TH Tyrosine hydroxylase  CGGGCTTCTCGGACCAGGTGTA  
CTCCTCGGCGGTGTACTCCACA  
VGAT (SLC32A1) Vesicular inhibitory amino acid 
transporter 
AGATGATGAGAAACAACCCCAG 
CACGACAAGCCCAAAATCAC   
VGLUT1 (SLC17A7) Vesicular glutamate transporter 1 AATAACAGCACGACCCACCGCG 
AGCCGTGTATGAGGCCGACAGT 
 
 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Generation of human GPCs from hESCs  
To initiate the differentiation, the hESCs were detached from the plate using accutase and dissociated to single 
cells and small cell clusters and kept in iPS-Brew XF medium on day 0 in ultra-low adhesion flasks to allow for 
embryoid body (EB) formation. On day 0 – day 1, the iPS-Brew XF medium was supplemented with 10 μM Y- 
27632 (ROCK inhibitor; Miltenyi) to improve the survival of single cells. On day 5, the medium was switched to 
neural induction medium (NIM), containing DMEM/F12 basal medium (Thermo Fisher), MEM Non-Essential 
Amino Acids (NEAA) Solution (Thermo Fisher), N2 supplement (Thermo Fisher), and Antibiotic-Antimycotic 
(Thermo Fisher), and supplemented with bFGF (20 ng/ml, Sigma-Aldrich) and Heparin (2 μg/ml, STEMCELL 
Technologies). On day 9, the EBs were attached on Poly-Ornithine/Laminin (PO/Lam) coated tissue culture 
plates and two days later the medium was changed to NIM + RA (0.1 μM, Sigma-Aldrich) and on day 16 the 
medium was changed to NIM/B27 medium + RA + Purmorphamine (1 μM, Millipore). Around day 26-29, the 
cells were detached from the plates and were seeded as clusters in ultra-low attachment plates. At this stage, the 
cell quality was assessed by ICC of PAX6, SOX1 and OLIG2 and by FC of CD133 and SSEA4. Following the 
detachment, the free-floating cell clusters were kept in NIM/B27 medium + Purmorphamine + bFGF (10 ng/ml) 
up until day 37.  
On day 37, the medium was changed to glial medium (GM) containing DMEM/F12 basal medium, B27 
supplement, N1 supplement (Sigma-Aldrich), MEM NEAA, Antibiotic-Antimycotic, T3 (60 ng/ml, Sigma- 
Aldrich), db-cAMP (1 μM, Sigma-Aldrich), Biotin (100 ng/ml, Sigma-Aldrich), recombinant human PDGF-AA 
protein (10 ng/ml, R&D Systems), recombinant human IGF-I (10 ng/ml, R&D Systems) and recombinant human 
NT-3 Protein (10 ng/ml, R&D Systems), and supplemented with Purmorphamine until day 55 when 
Purmorphamine was withdrawn from the medium. The cells were then kept in GM for the remaining time in 
culture. Around day 70, the free-floating clusters were manually cut into smaller pieces using disposable sterile 
scalpels under a dissection microscope and seeded onto PO/Lam coated tissue culture plates. Thereafter, the cells 
were passaged and expanded every 30 days, when the clusters were mechanically detached from the plates using 
a cell scraper, cut at the dissection microscope and re-seeded again at lower density. At every passage, the cells 
were analyzed by FC for CD44 and CD140 and by ICC for various glial markers. Table S1 specifies the number 
of days in culture and the proportion of CD140+/CD44+ of the hESC-derived cell batches used in this study.  
Cryopreservation of hESC-derived hGPCs 
For cryopreservation of the hESC-derived GPCs, the cell clusters were detached from the plate using a cell 
scraper, centrifuged at 300 x g for 7 min, resuspended in cold glial medium and dissociated using a 1000 μl 
pipette. The cells were cryopreserved at a density 0.5-1x 6-well per cryovial in 500 μl GM. The freezing medium 
was prepared by supplementing ProFreezeTM-CDM NAO Freezing Medium (2X, Lonza) with 15 % DMSO and 
was added dropwise to the cryovial containing the cell suspension at equal proportions (giving a final 
concentration of DMSO of 7.5 %). The cryovials were then moved into a controlled-rate alcohol-free cell 
freezing container and kept at -80°C overnight. The following day the cells were moved to a -150°C freezer or a 
Liquid Nitrogen tank for long-term storage. 
 
Electrophysiology 
Whole cell patch-clamp electrophysiological recordings were performed at day 60 and 100 post-conversion. 
Cells were cultured on glass coverslips and transferred to a recording chamber with constant flow of Krebs 
solution gassed with 95 % O2 – 5 % CO2 at room temperature. The composition of the standard solution was (in 
mM): 119 NaCl, 2.5 KCl, 1.3 MgSO4, 2.5 CaCl2, 25 Glucose and 26 NaHCO3. For recordings Multiclamp 700B 
amplifier (Molecular Devices) was used together with borosilicate glass pipettes (3–7 MOhm) filled with the 
following intracellular solution (in mM): 122.5 potassium gluconate, 12.5 KCl, 0.2 EGTA, 10 Hepes, 2 MgATP, 
0.3 Na3GTP and 8 NaCl adjusted to pH 7.3 with KOH as in (Pfisterer et al., 2011). Data acquisition was 
performed with pClamp 10.2 (Molecular Devices); current was filtered at 0.1 kHz and digitized at 2kHz. The 
cells were selected for recording based on their neuronal shape and clear surface, cells with signs of shrinkage or 
visualized nuclei were excluded. Resting membrane potentials were monitored immediately after breaking-in in 
current-clamp mode. Thereafter, cells were kept at a membrane potential of -60mV to -70mV, and 500ms 
currents were injected from -20pA to +90pA with 5pA increments to induce action potentials. For inward 
sodium and delayed rectifying potassium current measurements cells were clamped at -70mV and voltage-
depolarizing steps were delivered for 100ms at 10mV increments. Spontaneous AP were recorded in current-
clamp mode at resting membrane potentials. Addition of tetrodotoxin (TTX) to the Krebs solution to final 
concentration of 1 µM was performed in order to specifically block sodium channels and inhibit neuronal 
activity during recording.   
 
Flow cytometry analysis and FACS sorting 
For flow cytometry analysis of the cells between D130-270, the cell clusters were dissociated for 8 min in 
Accutase (StemPro; Thermo Fisher) and resuspended to 1 million cell/ml in Miltenyi wash buffer (PBS + 0.5% 
BSA Fraction V + 2 μM EDTA + 0.05‰ Phenol Red). For each staining, 100 ul cell suspension was used and 
the cells were incubated with fluorophore-conjugated antibodies for 15 min at 4°C (PE anti-human CD140a, BD 
Biosciences, cat. no. 556002, 1:10; APC anti-CD44 (Miltenyi, cat. no. 130-095-177, 1:500); APC anti-human 
CD133/1, (Miltenyi, cat. no. 130-113-668, 1:50); FITC anti-human SSEA-4, Biolegends, cat. no. 330410, 1:20). 
Following the 15 min incubation with the antibodies, the cells were washed with Miltenyi wash buffer, 
centrifuged for 10 min at 200 x g and transferred to 5 ml polystyrene tubes with cell-strainer caps at a final 
density of around 400,000 cells/ml in DMEM/F12 + DNase. To exclude dead cells, Propidium iodide (PI, 
Miltenyi, cat. no. 130-095-177, 1:500) was added to the samples. For each sample, 10,000 cells were analyzed 
on a FACSAria III sorter (BD Biosciences). Gates were set based on Fluorescence Minus One (FMO) controls 
and compensation was performed using single-stained cells. 
For CD140-based cell sorting, the same staining procedure was employed but the cells were stained at a higher 
density, with the same concentration of CD140a antibody (1:10). To improve the viability of the sorted cells, the 
sorting medium was supplemented with 10 μM Y-27632 and polypropylene tubes that had been precoated with 
3.4% BSA Fraction V in PBS overnight were used. The sorted cells were collected in glial medium 
supplemented with 1x B27 and 10 μM Y-27632.  For gating strategy for the FACS exeperiment, see Figure S4. 
 
 
Microscopy 
Fluorescent images were captured using a Leica DMI6000B widefield microscope. The image acquisition 
software was Leica LAS X and images were processed using Adobe Photoshop CC 2018. Any adjustments were 
applied equally across the entire image, and without the loss of any information. 
 
